Recent advances in lipid nanoparticles for delivery of nucleic acid, mRNA, and gene editing-based therapeutics

• Published in: Drug metabolism and pharmacokinetics Vol. 44; p. 100450
• Main Authors: Mukai, Hidefumi, Ogawa, Koki, Kato, Naoya, Kawakami, Shigeru
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.06.2022; The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd
• Subjects: Base editing; COVID-19 - therapy; DNA barcode; Gene Editing; Humans; Ionizable lipid; Lipid nanoparticle; Lipids; Liposomes; mRNA; Nanoparticles; Nucleic acid; Positron emission tomography; Recombination; Review; RNA, Messenger - genetics; Targeting; Recombination; Targeting; DNA barcode; Gene editing; Base editing; mRNA; Ionizable lipid; Positron emission tomography; Lipid nanoparticle; Nucleic acid
• ISSN: 1347-4367; 1880-0920; 1880-0920
• DOI: 10.1016/j.dmpk.2022.100450

Lipid nanoparticles (LNPs) are becoming popular as a means of delivering therapeutics, including those based on nucleic acids and mRNA. The mRNA-based coronavirus disease 2019 vaccines are perfect examples to highlight the role played by drug delivery systems in advancing human health. The fundamentals of LNPs for the delivery of nucleic acid- and mRNA-based therapeutics, are well established. Thus, future research on LNPs will focus on addressing the following: expanding the scope of drug delivery to different constituents of the human body, expanding the number of diseases that can be targeted, and studying the change in the pharmacokinetics of LNPs under physiological and pathological conditions. This review article provides an overview of recent advances aimed at expanding the application of LNPs, focusing on the pharmacokinetics and advantages of LNPs. In addition, analytical techniques, library construction and screening, rational design, active targeting, and applicability to gene editing therapy have also been discussed.